HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PRVA
Privia Health Group, Inc.
PRVA's fundamentals are strong and it looks cheap: trading at 88x earnings, below its usual 151x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PRVA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Healthy |
PRVA's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PRVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 54x | $23.67 | — |
| Current | 88x | $23.67 | — |
| Cheap | 90x | $24.32 | +2.7% |
| Fair | 150x | $40.60 | +72% |
| Expensive | 207x | $55.80 | +136% |
Historical ranges are pointers, not guarantees.
PRVA's PE is in its cheap range at 88x. If earnings grow as analysts expect, today's price would be 54x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PRVA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
PRVA has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PRVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.44 | +61% |
| Q3 2026 | $0.27 | +108% |
| Q2 2026 | $0.22 | +100% |
| Q1 2026 | $0.17 | +42% |
| Q4 2025 | $0.18 | +64% |
| Q3 2025 | $0.13 | +30% |
| Q2 2025 | $0.11 | -8.3% |
| Q1 2025 | $0.12 | -20% |
| Q4 2024 | $0.11 | -42% |
PRVA has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PRVA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PRVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $657M | +13% |
| Q2 2026 | $632.6M | +21% |
| Q1 2026 | $603.8M | +26% |
| Q4 2025 | $541.2M | +17% |
| Q3 2025 | $580.4M | +33% |
| Q2 2025 | $521.2M | +23% |
| Q1 2025 | $480.1M | +16% |
| Q4 2024 | $460.9M | +4.6% |
PRVA's revenue has grown year over year every quarter since early 2021: $657M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.1% | +0.6 points |
| Q2 2026 | 1.9% | +1.2 points |
| Q1 2026 | 1.2% | +0.1 points |
| Q4 2025 | 2.1% | +0.9 points |
| Q3 2025 | 2.5% | +1.1 points |
| Q2 2025 | 0.6% | -0.6 points |
| Q1 2025 | 1.1% | +0.9 points |
| Q4 2024 | 1.1% | +0.8 points |
PRVA has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PRVA on cash flow, with more consistent year-over-year improvement.
PRVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.9M | -44% |
| Q2 2026 | $1.1M | -86% |
| Q1 2026 | -$49.5M | -$25.4M |
| Q4 2025 | $127.5M | +70% |
| Q3 2025 | $52M | +57% |
| Q2 2025 | $8M | -77% |
| Q1 2025 | -$24.1M | +$9.1M |
| Q4 2024 | $74.8M | +17% |
PRVA generated $108M in free cash flow over the past year, down 2.4% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PRVA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PRVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +883K shares |
| 1 year | +3.1% | +3.9M shares |
| 3 years | +6.2% | +7.8M shares |
| 5 years | +25% | +26.8M shares |
| Available history | +29% | +29.9M shares |
PRVA has 133M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PRVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -7.0x | Net Cash |
| Q2 2026 | -7.2x | Net Cash |
| Q1 2026 | -8.8x | Net Cash |
| Q4 2025 | -10.9x | Net Cash |
| Q3 2025 | -11.8x | Net Cash |
| Q2 2025 | -14.1x | Net Cash |
| Q1 2025 | -16.3x | Net Cash |
| Q4 2024 | -20.3x | Net Cash |
PRVA has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PRVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.1 | Neutral |
| Stochastic | 71.7 | Neutral |
PRVA's weekly RSI is 55 (neutral) and its Stochastic is 72 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PRVA PE vs Healthcare Sector
| Metric | PRVA | Sector median | Relative |
|---|---|---|---|
| PE | 88x | 26x | 239% above |
| PE % | 15 | 36 | 21 pts below |
PRVA is trading at 88x earnings, a 239% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PRVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.9 | 8% above |
| 20 week MA | $22.7 | 4.4% above |
| 50 week MA | $22.9 | 3.4% above |
| 100 week MA | $22.9 | 3.6% above |
| 200 week MA | $22.6 | 4.9% above |
PRVA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PRVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $36.3 | $26.2 | -28% |
| 2022 | $26.2 | $23.4 | -11% |
| 2023 | $23.4 | $23.0 | -1.6% |
| 2024 | $23.0 | $19.9 | -14% |
| 2025 | $19.9 | $24.1 | +22% |
| 2026 YTD | $24.1 | $23.7 | -1.9% |
PRVA has the edge over HIMS on returns for 2026, with the stronger performance.